Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib
REDWOOD CITY, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea' or the 'Company') (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical data from the ongoing Phase I COVALENT-103 trial of BMF-500 in adults with relapsed or refractory ('R/R') acute leukemia ('AL'). The results will be presented in a poster presentation at the European Hematology Association ('EHA') 2025 Congress in Milan, Italy.
The presentation by Dr. Farhad Ravandi of The University of Texas MD Anderson Cancer Center will highlight emerging safety, pharmacokinetics/pharmacodynamics, and early clinical activity data for BMF-500, a highly selective covalent FMS-like tyrosine kinase 3 ('FLT3') inhibitor, in heavily pretreated patients with R/R AL.
Key Results from the EHA 2025 Poster Presentation27 patients were enrolled across two study arms, Arm A (no CYP3A4 inhibitor; n=10) and Arm B (CYP3A4 inhibitor; n=17). All patients had R/R AL, with a median of 4 prior lines of therapy. 18 of the 27 patients were FLT3 mutations ('FLT3m') while the other 9 patients had FLT3 wild-type AL. Frequent co-mutations included WT1, TP53, IDH1/2, and NRAS. All 18 FLT3m patients had failed gilteritinib in the R/R setting and 9 of the 18 had received at least two FLT3 inhibitors prior to study entry. 26 of 27 (96%) enrolled patients had also received and failed the BCL2 inhibitor venetoclax. Key findings include:
Clinical Activity Observed:
9 of 11 efficacy-evaluable FLT3m patients, defined as all patients enrolled who received at least one dose and had at least one disease assessment, showed bone marrow (BM) blast reduction; 5 of 11 achieved >50% BM blast reduction.
1 FLT3m patient achieved complete remission with incomplete hematologic recovery (CRi), sustained for 6 cycles.
1 FLT3m patient achieved morphologic leukemia-free state (MLFS); response is ongoing.
1 FLT3m patient met all criteria for partial response (PR) except platelet recovery; categorized as near PR.
2 of 4 efficacy-evaluable FLT3 wild-type patients achieved durable disease control ≥120 days, with treatment ongoing for one patient.
Additional clinical improvements include reductions in peripheral blasts, transfusion dependency, and frequency of hydroxyurea use.
Pharmacokinetics/Pharmacodynamics:
FLT3 inhibition correlated with BMF-500 systemic exposures.
Bone marrow and plasma concentrations of BMF-500 and its metabolites were comparable, suggesting good compartmental penetration.
Survival:
Median overall survival (mOS) among all treated FLT3m patients (n=18) was 3.8 months (Arm A) and 3.5 months (Arm B) during dose escalation.
For the efficacy-evaluable FLT3m patients (n=12), the mOS for Arms A and B was 3.8 and 3.6 months, respectively during dose escalation.
These survival durations compare favorably to historical mOS of 2.1 months in patients with R/R FLT3m acute myeloid leukemia ('AML') post-failure with both gilteritinib and venetoclax. 1
Ongoing Dose Escalation:
Dose escalation continues at 200 mg BID (Arm A) and 75 mg BID (Arm B).
Based on observed activity and tolerability, further evaluation is underway to determine optimal biologic dose ('OBD') and recommended Phase II dose ('RP2D').
Safety and Tolerability
BMF-500 was generally well-tolerated across dose levels.
No dose-limiting toxicities (DLTs), QT prolongation, or discontinuations due to treatment-related adverse events were reported.
Escalation is ongoing without safety restrictions.
'The updated COVALENT-103 results continue to support the potential of BMF-500 as a selective, covalent FLT3 inhibitor,' said Mick Hitchcock, Ph.D., Interim Chief Executive Officer of Biomea Fusion. 'We are encouraged by the depth of bone marrow responses, the achievement of MLFS and CRi, and the early survival benefit in heavily pretreated patients with FLT3 mutations who had progressed following prior FLT3 inhibitor therapy. These data speak to BMF-500's potential to meaningfully improve outcomes in a high-risk AML population with no currently available treatment options.'
Following completion of the COVALENT-103 dose escalation phase in R/R AL patients with FLT3m, Biomea plans to conclude its internal development of BMF-500 in oncology and is actively exploring strategic partnerships to advance the program.
Poster Presentation Details
Date/Time: Saturday, June 14 (18:30-19:30 CEST)
Title: Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the COVALENT-103 Study (NCT05918692)
Poster Number: PS1520
Presenter: Farhad Ravandi, M.D., University of Texas MD Anderson Cancer Center
About COVALENT-103 COVALENT-103 is a multicenter, open-label, non-randomized trial seeking to evaluate the safety and efficacy of BMF-500, a twice daily oral treatment, in adult patients with R/R AL with FLT3 wild-type or FLT3m. The Phase I COVALENT-103 study aims to evaluate the safety and tolerability of BMF-500, determine the optimal biologic dose and recommended Phase II dose, and identify initial efficacy signals. Additional information about the Phase I clinical trial of BMF-500 can be found at ClinicalTrials.gov using the identifier, NCT05918692.
About BMF-500 BMF-500 is an investigational, orally bioavailable, covalent small molecule inhibitor of FLT3, discovered in-house using Biomea's proprietary FUSION™ System. Designed to be highly potent and selective, BMF-500 has demonstrated encouraging potential in extensive preclinical studies. Its kinase inhibitory profile indicates strong target selectivity, which may translate to a reduced risk of off-target effects.
About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and other metabolic diseases. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X, and Facebook.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including BMF-500, the potential of BMF-500 as a treatment for patients with FLT3m R/R AL, our research, development, partnership and regulatory plans, and the timing of such events may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that preliminary or interim results of preclinical studies or clinical trials may not be predictive of future or final results in connection with future clinical trials and the risk that we may encounter delays in preclinical or clinical development, patient enrollment and in the initiation, conduct and completion of our ongoing and planned clinical trials and other research and development activities. These risks concerning Biomea's business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission (SEC), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Reference: 1. Corley et al. (P1798) HemaSphere 2024;8(S1), 3339-3340.
Contact: Meichiel Jennifer Weiss Sr. Director, Investor Relations and Corporate DevelopmentIR@biomeafusion.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Stifel Starts Uber Technologies, Inc. (UBER) at Buy, Cites Strong Growth
Uber Technologies, Inc. (NYSE:UBER) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Stifel initiated the 'Buy' rating for Uber Technologies, Inc. (NYSE:UBER), with a price target of $110, highlighting an upside of nearly 27%. The analysts believe the giant can meet or even exceed its 2024 targets, including mid-to-high-teens growth in gross bookings and a high EBITDA compound annual growth rate. The financials of the company reinforce a somewhat similar picture. Just recently, Uber Technologies, Inc. (NYSE:UBER) inked the acquisition of Taiwan fleet dispatcher Crown Taxi in an attempt to enhance its presence in the Taiwanese market. While the deal is pending regulatory approval, if successful, it can offer Crown Taxi professional drivers a smoother working experience and increase passenger, in general. A close up view of a hand holding a smartphone, using a ride sharing app. For a company like Uber Technologies, Inc. (NYSE:UBER), there's a lot to look forward to. The perfect blend of AI, ML, and cloud infrastructure positions the company as more than just a transportation provider. Given its record of losses, the company has managed to build a sustainable business model on the foundations of innovation and smart capital. Uber Technologies, Inc. (NYSE:UBER) is a California-based developer and operator of proprietary technology applications. With a global presence, the company has three main segments: Mobility, Delivery, and Freight. Founded in 2009, Uber is committed to creating opportunity through movement. While we acknowledge the potential of UBER as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Medscape
an hour ago
- Medscape
MRD: A Shared Compass for Patients, Clinicians, and Regulators
MILAN — The landscape of hematologic malignancies is shifting rapidly, in part due to the evolving significance of measurable (formerly "minimal") residual disease (MRD). Once confined to the realm of research, MRD is emerging as a critical tool for clinical and regulatory decision-making. In conditions such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and multiple myeloma (MM), MRD has become more than a marker of extent of disease burden; it now informs prognosis, therapeutic response, and access to novel treatments. "MRD is not a new concept; it has been studied for years", Jesus San Miguel Izquierdo, MD, PhD, director of clinical and translational medicine at the University of Navarra, Pamplona, Spain, told Medscape Medical News . Thanks to technological advances, unprecedented sensitivity in detecting residual cancer cells following treatment, in other words MRD, has been achieved. "We are capable of identifying a single tumor cell among a million," said San Miguel Izquierdo, who was awarded the 2025 EHA Lifetime Achievement Award for his lifelong work in MM. At a multidisciplinary session here at the European Hematology Association (EHA) 2025 Annual Meeting in Milan, representatives of patient organizations, clinicians, and regulatory bodies offered insights into the expanding role of MRD. Although its utility as an indicator of treatment response is widely recognized, debates remain over standardization, regulatory implications, and its intersection with patient experience and access. The Patient Voice: MRD as a Tool of Hope and Anxiety Anne-Pierre Pickaert, a survivor of ALL and patient advocate, described MRD in profoundly personal terms. For many patients, MRD is both a beacon and a burden. "It's like a needle in a haystack," she explained, noting that the absence of detectable cancer cells does not always equate to the absence of disease, and that uncertainty can be emotionally taxing. The terminology shift from "minimal" to "measurable" residual disease may have technical sense, but it can be unsettling for patients. "Minimal" is often interpreted as benign or reassuring, whereas "measurable" conveys clinical precision but may also amplify anxiety. Conversely, "minimal" can offer false reassurance, underestimating actual risk. There are also disparities in how MRD is communicated and understood across different hematologic diseases. For patients with ALL or AML, MRD status can dictate eligibility for transplants, trials, or access to novel therapies. In contrast, patients with chronic lymphocytic leukemia or lymphoma may be less familiar with the concept, reflecting its inconsistent use in routine care. Advocacy networks face challenges in delivering cohesive education across this diverse landscape. Pickaert also used the term "MRD-xiety," likening it to the "scanxiety" experienced by patients with solid tumors awaiting imaging results. As MRD often determines treatment direction, it carries substantial emotional weight. Yet most patients remain unaware of the regulatory frameworks that shape access to MRD-guided interventions. "We just want access," she said, be it through compassionate use, early access programs, or full reimbursement. Clinician Perspective: A Shift in Therapeutic Strategy Nicola Gökbuget, MD, head of the study center, department of hematology/oncology, University Cancer Center, Frankfurt, Germany, highlighted how MRD is transforming clinical strategy. Presenting an ALL case, she emphasized the paradigm shift from hematologic to molecular decision-making. "Historically, we acted on clinical relapse. Today, persistent or re-emerging MRD — as a molecular failure — can prompt therapeutic changes." This proactive model is influencing clinical trial designs and enabling more personalized approaches, such as targeting residual disease before transplant. In contrast, classical strategies relied on hematologic response and salvage therapy after hematologic progression. Still, the clinical utility of MRD depends on standardization. Clinicians need consensus definitions for response categories — complete molecular remission, intermediate response, molecular failure — as well as harmonized testing modalities and timepoints. Gökbuget stressed that the value of MRD risks being undermined without unified standards. Coordinated efforts from academic groups and industry partners will be essential. The Regulatory View: Is Surrogacy the Right Goal? Pierre Démolis, MD, PhD, chair of the Oncology Working Party and co-chair of the Scientific Advice Working Party at the European Medicines Agency, discussed the nuanced regulatory stance on MRD. Although MRD is a powerful indicator of response, it is not yet a validated surrogate endpoint. Surrogacy, in regulatory terms, requires consistent, reproducible correlation with overall survival across various contexts; something MRD has not fully achieved. Still, Démolis advocates for MRD as a "response trigger" in adaptive designs, transplant decisions, and early treatment assessments. "Let's stop pretending surrogacy is required to make MRD useful," he said. "It's like objective response rate or complete hematologic response; we've used such endpoints for decades." He clarified the distinction between activity and efficacy: activity refers to pharmacodynamic effects (eg, tumor shrinkage, MRD negativity), while efficacy denotes clinical benefit (eg, overall survival, progression-free survival). Activity-based endpoints such as MRD are already used in single-arm trials, particularly when randomized data are impractical. However, MRD should not replace overall survival as the final endpoint. "It can be used in conditional settings, provided final efficacy outcomes confirm its relevance," he added. Survey Shows Divergence in Attitudes Anna Smit, a PhD candidate at Erasmus MC Cancer Institute in Rotterdam, the Netherlands, presented preliminary findings from a joint EHA-International Myeloma Society survey on the role of MRD in MM trials. Among 389 healthcare professionals and 40 regulators surveyed, most supported MRD negativity as a primary endpoint, regardless of transplant eligibility. Nearly all respondents emphasized the need for global standardization. Yet variation in techniques and sensitivities remains a major barrier. Smit noted that in April 2024, the Oncologic Drugs Advisory Committee of the US Food and Drug Administration unanimously supported MRD-negative complete response as an endpoint to justify accelerated approval in MM. Europe, however, has not yet agreed to this and continues to monitor the field. Démolis confirmed ongoing global regulatory discussions on different topics, including MRD, highlighting monthly exchanges among agencies to share and possibly align perspectives. Patient-Centered Medicine Remains Paramount Quality of life (QoL) was also discussed during the session as another important aspect of the patient-centered approach to hematologic malignancies. For Pickaert, QoL is a non-negotiable endpoint: "Patients want survival, but not at any cost." Démolis echoed this view: "If you prolong life by a month but destroy QoL, is that meaningful?" Gökbuget acknowledged the practical difficulties of collecting QoL data, especially in acutely ill populations, but emphasized that such hurdles are not insurmountable. "Even when patients are unwell, someone can help complete the questionnaire," Pickaert said. Integrating QoL into MRD-based strategies could ensure that treatments extend not just life but also well-being. "As regulators, we must prioritize QoL in our decisions," Démolis said. San Miguel Izquierdo reinforced this message in a comment to Medscape Medical News . "Looking at MRD allows for early intervention," he said, implicitly linking early intervention to better QoL. Although some clinicians worry about overtreatment, the risk of undertreatment is often far greater. "By ignoring MRD, we risk undertreating 90% of patients and overtreating 10%," he concluded. Pickaert, Smit, and Démolis have reported no relevant financial relationships. Gökbuget has reported advisory board participation for and speaker honoraria and travel support from Amgen, AstraZeneca, Autolus, Celgene, Clinigen, Gilead, Incyte, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi, and Servier; and institutional research support from Amgen, Clinigen, Incyte, Jazz Pharmaceuticals, Novartis, and Servier. San Miguel Izquierdo has declared participation on advisory boards and consulting services, on behalf of his institution, for AbbVie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, Secura Bio, and Gilead-Kite.
Yahoo
an hour ago
- Yahoo
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs
Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a leading investment bank, has initiated a 'Buy' rating for Travere Therapeutics, Inc. (NASDAQ:TVTX), with a price target of $30, signaling an upside of around 100%. This confidence in the company underscores its position in the pharmaceutical sector. The company has just announced plans to present three new abstracts underscoring the impact of FILSPARI (sparsentan) in rare kidney disease at the International Podocyte Conference, taking place in Hamburg, Germany. The findings of FILSPARI, showcasing advanced reductions in urinary BAFF and sC5b9, along with dips in the proinflammatory and profibrotic biomarkers, signal a step forward in the treatment of IgAN. A laboratory technician working on a solution of rare diseases, housed in a cholic acid capsule. With net sales of FILSPARI increasing 182% year-over-year and the successful approval of FILSPARI in Europe and the UK, analysts have little doubt about the company's potential. Since the major revenue contribution comes from FILSPARI, the rising popularity and increasing adoption among nephrologists mean that Travere Therapeutics, Inc. (NASDAQ:TVTX) can continue to leverage a product that is quite differentiated. Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company incorporated in 2008. This California-based giant recognizes, develops, and commercializes therapies for people suffering from rare kidney and metabolic diseases in the United States. While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
